Background
Methods
Study cohort
Techniques
TACE procedure
Iodine 125 seeds implantation
Radiofrequency ablation
Assessment of clinical outcomes and follow-up
Statistical analysis
Propensity score matching and inverse probability of treatment weighting
Before PSM | After PSM | |||||
---|---|---|---|---|---|---|
Characteristics | TACE-Iodine 125 group | TACE-RFA group | P value | TACE-Iodine 125 group | TACE-RFA group | P value |
Age (Years) | 58.2 ± 9.7 | 57.7 ± 8.9 | 0.787 | 58.1 ± 10 | 57.6 ± 8.2 | 0.824 |
ALT (U/L) | 39.9 ± 20.6 | 48.8 ± 40.9 | 0.211 | 39.7 ± 20.9 | 45.9 ± 27.6 | 0.287 |
Hemoglobin (g/L) | 122.2 ± 22.1 | 127 ± 22.4 | 0.284 | 122.2 ± 23 | 127.4 ± 24 | 0.361 |
Platelet (×109/L) | 116 ± 58.5 | 131.1 ± 68.5 | 0.250 | 119 ± 59.7 | 138.7 ± 72.4 | 0.218 |
Lymphocyte(×109/L) | 1.2 ± 0.6 | 1.3 ± 0.6 | 0.786 | 1.2 ± 0.6 | 1.2 ± 0.6 | 0.911 |
Neutrophil (×109/L) | 3.2 ± 2.6 | 3.1 ± 1.7 | 0.712 | 3.3 ± 2.6 | 3.2 ± 1.9 | 0.939 |
Leukocyte (×109/L) | 5.2 ± 3.1 | 5 ± 2.3 | 0.763 | 5.2 ± 3.2 | 5.2 ± 2.5 | 0.937 |
Gender (male, %) | 78.9 | 87.8 | 0.214 | 80 | 88.6 | 0.324 |
HBV(+, %) | 63.2 | 75.7 | 0.165 | 65.7 | 68.6 | 0.799 |
AFP (>200μg/L, %) | 21.1 | 23 | 0.817 | 22.9 | 34.3 | 0.290 |
TACE number (≥2, %) | 89.5 | 73 | 0.044 | 88.6 | 82.9 | 0.495 |
Tumor number (≥2, %) | 65.8 | 35.1 | 0.002 | 62.9 | 60 | 0.806 |
Tumor size (> 3 cm, %) | 65.8 | 56.8 | 0.356 | 34.3 | 20 | 0.179 |
CHILD (B, %) | 34.2 | 23 | 0.204 | 37.1 | 28.6 | 0.445 |
BCLC (B, %) | 68.4 | 41.9 | 0.008 | 65.7 | 82.9 | 0.101 |
Results
Patients
Overall survival and progression free survival
Characteristics | HR (95%CI) | P value | Adjusted HR (95%CI) | P value |
---|---|---|---|---|
Overall | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine 125 | 0.957 (0.538,1.704) | 0.556 | 0.763 (0.403,1.345) | 0.320 |
Child-Pugh A | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine 125 | 1.001 (0.513,1.953) | 0.998 | 0.822 (0.414,1.633) | 0.576 |
Child-Pugh B | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine 125 | 1.095 (0.331,3.621) | 0.882 | 0.538 (0.124,2.342) | 0.409 |
BCLC A | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine 125 | 0.854 (0.242,3.009) | 0.806 | 0.496 (0.125,1.973) | 0.319 |
BCLC B | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine | 0.826 (0.425,1.606) | 0.573 | 0.834 (0.422,1.650) | 0.603 |
Characteristics | HR (95%CI) | P value | Adjusted HR (95%CI) | P value |
---|---|---|---|---|
Overall | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine 125 | 1.252 (0.805,1.950) | 0.319 | 1.020 (0.645,1.611) | 0.934 |
Child-Pugh A | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine 125 | 1.270 (0.749,2.154) | 0.374 | 0.976 (0.566,1.685) | 0.932 |
Child-Pugh B | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine 125 | 1.416 (0.598,3.354) | 0.429 | 1.539 (0.560,4.232) | 0.403 |
BCLC A | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine 125 | 0.816 (0.352,1.893) | 0.636 | 0.601 (0.234,1.547) | 0.291 |
BCLC B | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine | 1.253 (0.724,2.169) | 0.421 | 1.252 (0.722,2.171) | 0.423 |
Characteristics | Mortality | Recurrence | ||
---|---|---|---|---|
Adjusted HR (95%CI) | P value | Adjusted HR (95%CI) | P value | |
Overall | ||||
TACE-RFA | Reference | Reference | ||
TACE-Iodine 125 | 0.766 (0.384,1.530) | 0.450 | 1.220 (0.711,2.093) | 0.470 |
Complications
Adverse events | Grade I and II | Grade III and IV | ||||
---|---|---|---|---|---|---|
TACE-RFA | TACE-Iodine 125 | P value | TACE-RFA | TACE-Iodine 125 | P value | |
Fatigue | 10 | 12 | 0.607 | 1 | 1 | > 0.99 |
Nausea | 8 | 8 | > 0.99 | 0 | 1 | > 0.99 |
Fever | 3 | 7 | 0.172 | 0 | 0 | > 0.99 |
Leucopenia | 0 | 6 | 0.003 | 0 | 0 | > 0.99 |
Liver pain | 25 | 24 | 0.794 | 2 | 2 | > 0.99 |
Hepatic hemorrhage | 3 | 2 | 0.642 | 1 | 0 | > 0.99 |
Increased ALT | 6 | 14 | 0.034 | 3 | 6 | 0.280 |
Pneumothorax | 2 | 4 | 0.389 | 0 | 0 | > 0.99 |